Co-diagnostics, inc. commemorates third anniversary of the completion of its first covid-19 test design

Designed using the company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33 million sold worldwide; company also announces participation in life sciences day on the hill on jan 27 salt lake city , jan. 24, 2023 /prnewswire/ -- co-diagnostics, inc. (nasdaq-cm: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, yesterday commemorated the third anniversary of the completion of the principal design work of a co-primers™ pcr test for what was, on january 23, 2020, still known as 2019-ncov, or the novel coronavirus. the initial design was rapidly completed using the company's proprietary co-dx™ design platform.
CODX Ratings Summary
CODX Quant Ranking